Absci Q3 2026: December hair-loss data is the only number that matters

Absci posted a Q3 loss of $0.19 per share, beating the Wall Street estimate of roughly $0.20. That narrow beat came even as the company's net loss widened to $33.3 million from $28.71 million a year earlier, with the per-share figure helped by a larger share count.

Revenue of $304,000, drawn entirely from partner programs, missed the $581,700 consensus and fell from the year-ago period. For a company carrying a $1.7 billion market cap, those numbers are almost beside the point: Absci is a clinical-stage AI drug designer, and the quarterly revenue line reflects a handful of partner arrangements rather than any commercial product.

Everything for investors turns on the HEADLINE trial of ABS-201, an anti-PRLR antibody being tested in pattern hair loss. All three dosing cohorts in the multiple-ascending-dose phase are fully enrolled, and 13-week interim proof-of-concept data are expected in December 2026, with full 26-week results to follow in early 2027. The company is also evaluating a direct move for ABS-201 from Phase 1/2a to Phase 3, and plans to engage the FDA on that question.

Absci ended the quarter with $173.7 million in cash, cash equivalents, and marketable securities, a runway the company projects will fund operations into the second half of 2028. That gives management enough time to absorb the December data readout and, if results support it, advance into a larger Phase 2 endometriosis trial targeted for mid-2027.

CEO Sean McClain described the company as excited to get its first look at proof-of-concept data for ABS-201 next month, framing the opportunity around demonstrating the program's ability to stimulate hair regrowth in a convenient and durable way. Absci also appointed former Galderma executive Gerry Muhle as Chief Commercial Officer, signaling the company is beginning to build a commercial infrastructure well ahead of any potential approval.